---
title: "Lysergide (DT120) in Generalized anxiety disorder: Benzodiazepines"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Benzodiazepines. Topics: FDA-approved indication: alprazolam; Approval status and off-label use of individual benzodiazepines; FDA boxed warning for the benzodiazepine class, September 2020; Benzodiazepine prescribing, misuse, and overdose data; 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/benzodiazepines"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Benzodiazepines

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Benzodiazepines

<a id="topic-2.2.2.1.6-1"></a>

### FDA-approved indication: alprazolam

> “XANAX is indicated for the:”
> “acute treatment of generalized anxiety disorder (GAD) in adults.”
> “XANAX was significantly better than placebo at each of the evaluation periods of these 4-week studies”

Source: [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Approval status and off-label use of individual benzodiazepines

> “As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD. However, clonazepam, lorazepam, and diazepam are often used to treat GAD in adults”
> “Benzodiazepines such as diazepam and clonazepam (both of which are long-acting agents) may be efficacious in treating GAD, although many clinicians choose to limit their use due to concerns about the risks regarding possible misuse and dependence.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.6-3"></a>

### FDA boxed warning for the benzodiazepine class, September 2020

> “To address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions, the U.S. Food and Drug Administration (FDA) is requiring the Boxed Warning be updated for all benzodiazepine medicines.”
> “However, even when taken at recommended dosages, their use can lead to misuse, abuse, and addiction.”
> “Physical dependence can occur when benzodiazepines are taken steadily for several days to weeks, even as prescribed. Stopping them abruptly or reducing the dosage too quickly can result in withdrawal reactions, including seizures, which can be life-threatening.”
> “Benzodiazepines are a class of medicines approved to treat generalized anxiety disorder, insomnia, seizures, social phobia, and panic disorder.”

Source: [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class)

<a id="topic-2.2.2.1.6-4"></a>

### Benzodiazepine prescribing, misuse, and overdose data

> “In 2018, an estimated 50% of patients who were dispensed oral benzodiazepines received them for a duration of two months or longer.”
> “In 2018, an estimated 5.4 million U.S. individuals 12 years and older abused or misused benzodiazepines in the previous year.”
> “Benzodiazepine-involved overdose deaths increased from 1,298 in 2010 to 11,537 in 2017.”

Source: [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class)

<a id="topic-2.2.2.1.6-5"></a>

### Boxed warning in the alprazolam prescribing information

> “The use of benzodiazepines, including XANAX, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.”
> “The continued use of benzodiazepines, including XANAX, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose.”
> “In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months”

Source: [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

### NICE guideline: short-term use during crises only

> “Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.6-7"></a>

### CANMAT guideline: second-line agents for short-term use

> “While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.”
> “Within these second-line agents, benzodiazepines would be considered first in most cases, except where there is a risk of substance abuse, while bupropion XL would likely be reserved for later.”
> “Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.6-8"></a>

### BAP guideline: use after nonresponse to other treatments

> “Benzodiazepines will usually be reserved for the further treatment of patients who have not responded to at least three previous treatments (such as after non-response to both an SSRI and an SNRI and a psychological intervention)”
> “Consider use of benzodiazepines after a non-response to SSRI, SNRI, pregabalin and buspirone treatment”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.6-9"></a>

### AAFP review: onset, dependence, and position in therapy

> “Benzodiazepines have the benefit of quick onset and are effective in treating symptoms of anxiety; however, they are associated with withdrawal, rebound anxiety, and dependence and are not recommended for long-term use.”
> “Benzodiazepines are not more effective than anti-depressants for anxiety disorders and should not be used as first-line therapy.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.6-10"></a>

### Meta-analysis: benzodiazepines compared with SSRIs and SNRIs

> “A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).”
> “SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.6-11"></a>

### Network meta-analysis: tolerability

> “Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
